Istituto Nazionale Tumori, IRCCS, Fondazione G. Pascale

Naples 80131

8 studies enrolling now · 30 studies all time

What they study most

Adult Disease, Advanced Melanoma, Advanced Non-Small Cell Lung Cancer, Advanced Renal Cell Carcinoma, Advanced Solid Tumor, Advanced or Metastatic Solid Tumor, B-cell Lymphoma, Bladder Carcinoma in Situ (CIS), Breast Cancer, Carcinoma, Cholangiocarcinoma, Colorectal Cancer

Studies at this site

• LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve — Recruiting now
• Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7 — Recruiting now
• Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors — Recruiting now
• Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer — Recruiting now
• A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 ) — Recruiting now
• Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation — Recruiting now
• Study of Sacituzumab Govitecan in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment — Recruiting now
• Outcomes of Low-Risk Endometrial Cancer With Isolated Tumor Cells in the Sentinel Lymph Nodes: A Prospective, Multicenter, Single-Arm Observational Study — Recruiting now
• A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies — Running, not enrolling
• Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma — Running, not enrolling
• Study of ONCOFID-P-B (PACLITAXEL-HYALURONIC ACID) — Running, not enrolling
• A Study of HFB200603 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors — Running, not enrolling
• Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2) — Running, not enrolling
• Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma — Running, not enrolling
• A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma — Running, not enrolling
• Study of Vimseltinib for Tenosynovial Giant Cell Tumor — Running, not enrolling
• Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors — Running, not enrolling
• A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma — Running, not enrolling
• A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma — Running, not enrolling
• Efficacy and Safety of Gadopiclenol for Body Magnetic Resonance Imaging (MRI) — Completed
• Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy — Running, not enrolling
• A Study of ANV419 Alone or in Combination With Approved Treatment in Patients With Cutaneous Melanoma (OMNIA-1). — Completed
• Safety and Diagnostic Efficacy of Mangoral in Participants With Focal Liver Lesions and Reduced Kidney Function — Completed
• Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients With Relapsed or Refractory Hodgkin Lymphoma — Completed
• Tavo and Pembrolizumab in Patients With Stage III/IV Melanoma Progressing on Either Pembrolizumab or Nivolumab Treatment — Status unconfirmed
• CANTATA: CB-839 With Cabozantinib vs. Cabozantinib With Placebo in Patients With Metastatic Renal Cell Carcinoma — Completed
• A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors — Completed
• HER-Seq: A Blood-based Screening Study to Identify Patients With HER2 Mutations for Enrollment Into Clinical Research Studies of Neratinib — Stopped early
• Sym004 Versus Futuximab or Modotuximab in Patients With mCRC — Stopped early
• MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients — Stopped early